Omeros Corporation to Showcase Research at ASH Annual Meeting
Omeros Corporation (Nasdaq: OMER) is set to present groundbreaking research focused on zaltenibart (OMS906), an investigational therapy aimed at targeting MASP-3, a pivotal activator in the complement system’s alternative pathway. This important presentation will take place during the American Society of Hematology (ASH) Annual Meeting, where the focus will be on the treatment of paroxysmal nocturnal hemoglobinuria (PNH) — a serious and rare blood disorder.
Details on Presentations
Two abstracts related to zaltenibart will be unveiled at the conference scheduled from December 7 to December 10. These presentations could potentially provide new insights into the treatment options available for patients suffering from PNH. Enrollment for further clinical trials involving zaltenibart is on the horizon, expected to commence in early 2025, ensuring a continued commitment to advancing treatment for this challenging disease.
First Presentation Overview
The first presentation focuses on the effectiveness of zaltenibart as a monotherapy. It highlights interim results from a Phase 2 proof-of-concept study, indicating improvements in key hematologic parameters among patients who previously had a suboptimal response to existing therapies such as Ravulizumab. This session, designated as Abstract Number 4072, is set for December 9, 2024, at the San Diego Convention Center.
Second Presentation Insights
Complementing the first, the second presentation delves into the pharmacokinetics and pharmacodynamics of zaltenibart as it pertains to both healthy individuals and PNH patients. Identified as Abstract Number 4081, this presentation will provide essential information on how zaltenibart interacts within the body, offering valuable data at the same session time and location.
Availability of Presentation Materials
Following these exciting presentations, Omeros will make the associated materials accessible on their official website. This initiative underscores the company's dedication to keeping stakeholders informed about the latest developments in their research efforts.
Understanding OMS906
OMS906 represents a significant advancement in the treatment of various complement-mediated diseases. By specifically targeting MASP-3, OMS906 aims to inhibit the alternative pathway of the complement system, a crucial element in the body’s immune defense. Unlike other complementary blockers, this new class of inhibitors preserves the classical pathway, which is vital for responding to infections. The implications of such targeted therapies could span a wide range, addressing conditions such as hemolytic uremic syndrome, traumatic brain injury, and beyond.
About Omeros Corporation
Omeros Corporation is a pioneering biopharmaceutical organization focused on developing first-in-class therapeutics for complex diseases. With an extensive pipeline that includes drugs for immunological disorders, such as narsoplimab — currently under FDA review — Omeros is committed to making a difference in patients' lives through innovative science. Through their research on various MASP inhibitors, the company strives to transform the treatment landscape for both common and rare diseases alike. More information about their ongoing projects can be found on their website.
Frequently Asked Questions
What is Zaltenibart (OMS906)?
Zaltenibart is an investigational therapy targeting MASP-3, aimed at treating paroxysmal nocturnal hemoglobinuria (PNH).
When will the ASH Annual Meeting be held?
The ASH Annual Meeting is scheduled for December 7 to December 10, 2024.
What are the main topics of the presentations?
The presentations will cover the effects of zaltenibart on patients with PNH and its pharmacokinetics.
Where can I find the presentation materials?
Presentation materials will be made available on Omeros' official website following the congress.
What does Omeros Corporation specialize in?
Omeros specializes in developing novel therapeutics for a range of immunologic and hematological disorders.
